Short answer
Gossamer Bio, Inc. (GOSS) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
Gossamer Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release attached as Exhibit 99.1, containing detailed results
- Disclosure furnished under Regulation FD, not treated as filed under Exchange Act Section 18
Item EX-99.1 · Exhibit EX-99.1
- FDA minutes support September 2026 NDA submission for seralutinib, with potential approval decision in Q3 2027 if accepted
- Worldwide seralutinib rights reacquired from Chiesi, adding full control and economics while requiring capped royalties and milestones
- Cash and marketable securities $57.0M, funding operations into Q1 2027 and highlighting near-term financing risk
- Debt reduced $115.9M through exchange, but new $65.2M 7.50% secured notes due 2030 remain
- Q2 net income $16.9M benefited from $43.8M debt extinguishment gain, while operating loss remained $26.1M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Gossamer Bio, Inc. 8-K filings
Get the next GOSS 8-K as it lands
Follow GOSS for push alerts, or ask the research agent what this filing means.